Barclays Maintains Overweight on Exact Sciences, Raises Price Target to $75
What to Expect From Neurocrine Biosciences's Earnings
Earnings Outlook For Vertex Pharmaceuticals
Liquidia Surges 15% as Court Clears Way for Yutrepia Launch
Peering Into Natera's Recent Short Interest
Trupanion Posts Better-Than-Expected Results, Joins Duolingo, DexCom, Exact Sciences And Other Big Stocks Moving Higher On Friday
Cancer Diagnostic Firm Exact Sciences' CEO Says Strong Q1 Paves Way For 'Transformative' 2025, Lifts Annual Guidance
Evercore ISI Group Maintains Outperform on Exact Sciences, Raises Price Target to $66
Exact Sciences Analyst Ratings
Apple To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Friday
Chardan Capital Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $325
Alnylam Pharmaceuticals Analyst Ratings
Why Twilio Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket
Earnings Call Summary | Exact Sciences(EXAS.US) Q1 2025 Earnings Conference
After-market Movers: Stock Futures up Despite Apple, Amazon Falling After Earnings
12 Health Care Stocks Moving In Thursday's After-Market Session
Exact Sciences Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Sales Results and Raised Its FY25 Sales Guidance.
Exact Sciences Raises FY2025 Sales Guidance From $3.02B-3.08B to $3.07B-3.12B
Correction: Exact Sciences Q1 Adj. EPS $(0.54) Misses $(0.38) Estimate, Sales $707.00M Beat $688.64M Estimate
United Therapeutics Analyst Ratings